Blog

Viking Therapeutics Achieves Breakthrough Results in X-ALD Treatment Trial for VK0214

Mike Cianciabella | October 10, 2024

Responsive image

Viking Therapeutics Reports Positive Data in Trial for X-ALD Treatment

Promising Results for VK0214

Viking Therapeutics Inc., a San Diego-based biopharmaceutical company, announced on Wednesday that it has achieved positive results from an early-stage trial for VK0214, a treatment aimed at the rare metabolic disorder X-linked adrenoleukodystrophy (X-ALD). X-ALD is a severe condition that usually presents during childhood, leading to life-threatening complications due to a build-up of very long-chain fatty acids (VLCFAs) in the body. Importantly, there are currently no approved treatments for this disorder.

The Phase 1b clinical trial for VK0214 involved adult male patients with adrenomyeloneuropathy (AMN), a form of X-ALD. In the trial, patients were allocated into three cohorts: a placebo group and two treatment groups receiving VK0214 at dosages of 20 mg and 40 mg daily. The primary endpoint of the study was to evaluate the safety and tolerability of VK0214 over a 28-day treatment period, while secondary objectives assessed the pharmacokinetics of the drug and its effects on plasma levels of VLCFAs.

Key Findings and Implications

Viking revealed that patients treated with VK0214 experienced significant reductions in mean VLCFA levels, a result indicating the treatment’s potential efficacy. “Patients receiving VK0214 demonstrated progressive improvement in plasma levels of very long chain fatty acids in the relatively brief treatment period evaluated in this study,” stated Brian Lian, CEO of Viking Therapeutics. Additionally, VK0214 displayed benefits regarding broader plasma lipids, including low-density lipoprotein cholesterol (LDL-C), which are vital for overall cardiometabolic health.

As X-ALD leads to severe complications including cognitive impairment and motor skill deterioration, the positive data reported are a hopeful sign for future treatment options. Viking plans to continue the development of VK0214, positioning it as a critical candidate for addressing this unmet medical need.

Market Reaction and Analyst Insights

The stock market initially reacted positively to Viking’s announcement, although the company’s stock later experienced a decline of 3.8% in morning trading. However, it is noteworthy that Viking’s stock has surged by 245% year-to-date, primarily driven by heightened interest in its weight-loss treatment, VK2735.

Analysts from Maxim Group remarked on the positive nature of the trial results but emphasized that attention remains focused on the weight-loss drug. They suggested that Viking might eventually consider partnering VK0214 for further development, underscoring the competitive landscape in the biopharmaceutical industry. All 13 analysts covering Viking on FactSet have issued buy ratings, further solidifying the positive outlook for the company.

A Broader Vision: The Weight-Loss Pill VK2735

In addition to VK0214, Viking Therapeutics is concurrently developing its oral weight-loss treatment, VK2735. Marketed as a cheaper entry point for investors interested in the burgeoning weight-loss pharmaceuticals sector, VK2735 is designed to target two gut hormones: GLP-1 and GIP, akin to Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy.

One key differentiator that Viking intends to explore is the potential for monthly dosing of VK2735. This contrasts with the existing treatments that require weekly injections, which often lead to issues with patient adherence. Maxim analysts have suggested that a once-monthly option could provide an attractive proposition for patients, enhancing compliance and treatment outcomes.

Conclusion

The announcement of promising trial results for VK0214 against X-ALD not only highlights the commitment Viking Therapeutics has towards addressing rare metabolic disorders but also underscores a broader strategic focus on obesity treatment. With a robust buy rating across analysts, Viking’s portfolio is gaining credibility as a potential game-changer in both rare disease management and weight-loss solutions.

As Viking pursues the further development of VK0214 and VK2735, investors, analysts, and patients alike will be watching closely to see how the company navigates its course in the biopharmaceutical landscape, aiming to bring new hope to those suffering from severe conditions.